Observational study reveals cytotoxic CD8+ T cell presence is crucial for bispecific antibody anti-lymphoma activity, suggesting potential treatment strategies.
Key Points
To investigate the role of distinct T cell subsets in bispecific antibody-mediated anti-lymphoma responses in B-cell non-Hodgkin lymphomas.
Analyzed tumor samples from 22 patients using flow cytometry and single-cell profiling techniques.
Performed in vitro cytotoxicity assays with polarized CD4+ and CD8+ T cells co-cultured with RAJI B cells and bispecific antibodies.
Used a B-NHL mouse model to assess the effects of CD20xCD3 bispecific antibodies on survival and T cell dynamics.
Patients with disease progression had significantly reduced CD8+ T cell infiltration compared to those who remained progression-free (p=0.035).
Cytotoxic CD8+ T cells showed robust target cell killing, whereas CD4+ Tregs and Tfh cells showed minimal killing.
In vivo studies indicated that CD8+ T cells are essential for the anti-tumor activity of bispecific antibodies and increased survival in treated mice.